Femasys (FEMY) Total Non-Current Liabilities (2020 - 2026)
Femasys (FEMY) reported Total Non-Current Liabilities of $6.1 million for Q1 2026, up 320.16% on a YoY basis from $1.4 million in Q1 2025, and down 46.07% quarter-over-quarter from $11.2 million in Q4 2025.
Femasys (FEMY) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends
Femasys has reported Total Non-Current Liabilities for 7 years, with the latest figure at $6.1 million in Q1 2026.
- For the quarter ending Q1 2026, Total Non-Current Liabilities rose 320.16% year-over-year to $6.1 million; the trailing twelve-month figure through Mar 2026 stood at $6.1 million (up 320.16% YoY), and the FY2025 full-year result was $11.2 million, up 620.2% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $6.1 million, down from $11.2 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $11.2 million in Q4 2025, with the low at $56245.0 in Q2 2023.
- Historically, Total Non-Current Liabilities has averaged $3.1 million across 5 years, with a median of $1.4 million in 2025.
- Annual changes were most pronounced in 2024 — Total Non-Current Liabilities soared 11567.19% — and 2025, when it tumbled 82.33%.
- Femasys' Total Non-Current Liabilities stood at $125242.0 in 2022, then jumped by 4969.53% to $6.3 million in 2023, then plunged by 75.47% to $1.6 million in 2024, then soared by 620.2% to $11.2 million in 2025, then plunged by 46.07% to $6.1 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $6.1 million (Q1 2026), $11.2 million (Q4 2025), and $1.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 148.09 Bn | 143.69 Bn | 1.83 Bn | 1.91 Bn |
| 2 | Becton Dickinson | 41.00 Bn | 39.99 Bn | 2.15 Bn | 24.24 Bn |
| 3 | Medline | 30.38 Bn | 36.22 Bn | 1.84 Bn | 17.13 Bn |
| 4 | Resmed | 28.22 Bn | 26.56 Bn | 890.98 Mn | 941.16 Mn |
| 5 | West Pharmaceutical Services | 23.72 Bn | 23.19 Bn | 296.40 Mn | 1.03 Bn |
| 6 | Solventum | 13.33 Bn | 13.33 Bn | 1.10 Bn | 8.65 Bn |
| 7 | Cooper Companies | 13.12 Bn | 12.99 Bn | 735.40 Mn | 3.98 Bn |
| 8 | Align Technology | 12.86 Bn | 11.80 Bn | 736.59 Mn | 2.10 Bn |
| 9 | Baxter International | 10.51 Bn | 8.47 Bn | 891.00 Mn | 12.54 Bn |
| 10 | Femasys | 254.59 Mn | 249.20 Mn | - | 6.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.05 Mn |
| Dec 31, 2025 | 11.22 Mn |
| Sep 30, 2025 | 1.19 Mn |
| Jun 30, 2025 | 1.31 Mn |
| Mar 31, 2025 | 1.44 Mn |
| Dec 31, 2024 | 1.56 Mn |
| Sep 30, 2024 | 6.75 Mn |
| Jun 30, 2024 | 6.56 Mn |
| Mar 31, 2024 | 6.41 Mn |
| Dec 31, 2023 | 6.35 Mn |
| Sep 30, 2023 | 2.22 Mn |
| Jun 30, 2023 | 56,245.00 |
| Mar 31, 2023 | 98,818.00 |
| Dec 31, 2022 | 125,242.00 |
| Sep 30, 2022 | 217,577.00 |
| Jun 30, 2022 | 318,237.00 |
| Mar 31, 2022 | 407,573.00 |
| Dec 31, 2021 | 552,208.00 |
| Sep 30, 2021 | 690,767.00 |
| Jun 30, 2021 | 788,469.00 |